The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives

References

• Agargun MY, Cilli AS, Kara H, Tarhan N, Kincir F, Oz H. Repetitive and frightening dreams and suicidal behavior in patients with major depression. Compr Psychiatry 1998; 39: 198–202
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders4th ed, (DSM-IV). Washington, DC: American Psychiatric Press.
   Google Scholar
• Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58: 19–36
   PubMed Web of Science ®Google Scholar
• Argyropoulos SV, Wilson SJ. Sleep disturbances in depression and the effects of antidepressants. Int Rev Psychiatry 2005; 17: 237–245
   PubMed Web of Science ®Google Scholar
• Armitage, R. 2007. Sleep and circadian rhythms in mood disorders. Acta Psychiatr Scand. Suppl: 104–115.
   Google Scholar
• Armitage R, Rush AJ, Trivedi M, Cain J, Roffwarg HP. The effects of nefazodone on sleep architecture in depression. Neuropsychopharmacology 1994; 10: 123–127
   PubMed Web of Science ®Google Scholar
• Armitage R, Yonkers K, Cole D, Rush AJ. A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients. J Clin Psychopharmacol 1997; 17: 161–168
   PubMed Web of Science ®Google Scholar
• Aslan S, Isik E, Cosar B. The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers. Sleep 2002; 25: 677–679
   PubMed Web of Science ®Google Scholar
• Asnis GM, Chakraburtty A, DuBoff EA, et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry 1999; 60: 668–676
   PubMed Web of Science ®Google Scholar
• Bellipanni G, Bianchi P, Pierpaoli W, Bulian D, Ilyia E. Effects of melatonin in perimenopausal and menopausal women: a randomized and placebo controlled study. Exp Gerontol 2001; 36: 297–310
   PubMed Web of Science ®Google Scholar
• Bellipanni G, Di Marzo F, Blasi F, Di Marzo A. Effects of melatonin in perimenopausal and menopausal women: our personal experience. Ann NY Acad Sci 2005; 1057: 393–402
   PubMed Web of Science ®Google Scholar
• Benca RM, Obermeyer WH, Thisted RA, Gilllin JC. Sleep and psychiatric disorders. A meta-analysis. Arch Gen Psychiatry. 1992; 49(8)651–68
   PubMed Web of Science ®Google Scholar
• Berger M, Riemann D. Symposium: Normal and abnormal REM sleep regulation: REM sleep in depression-an overview. J Sleep Res 1993; 2: 211–223
   PubMed Web of Science ®Google Scholar
• Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006; 7: 137–151
   PubMed Web of Science ®Google Scholar
• Borbely AA, Tobler I, Loepfe M, et al. All-night spectral analysis of the sleep EEG in untreated depressives and normal controls. Psychiatry Res 1984; 12: 27–33
   PubMed Web of Science ®Google Scholar
• Borjigin J, Li X, Snyder SH. The pineal gland and melatonin: molecular and pharmacologic regulation. Annu Rev Pharmacol Toxicol 1999; 39: 53–65
   PubMed Web of Science ®Google Scholar
• Cajochen C. TAK-375 Takeda. Curr Opin Investig Drugs 2005; 6: 114–121
   PubMedGoogle Scholar
• Cajochen C, Brunner DP, Krauchi K, Graw P, Wirz-Justice A. EEG and subjective sleepiness during extended wakefulness in seasonal affective disorder: circadian and homeostatic influences. Biol Psychiatry 2000; 47: 610–617
   PubMed Web of Science ®Google Scholar
• Cajochen C, Krauchi K, Mori D, Graw P, Wirz-Justice A. Melatonin and S-20098 increase REM sleep and wake-up propensity without modifying NREM sleep homeostasis. Am J Physiol 1997; 272: R1189–R1196
   PubMed Web of Science ®Google Scholar
• Cartwright R, Baehr E, Kirkby J, Pandi-Perumal SR, Kabat J. REM sleep reduction, mood regulation and remission in untreated depression. Psychiatry Res. 2003; 121(2)159–67
   PubMed Web of Science ®Google Scholar
• Celada P, Puig M, Amargos-Bosch M, Adell A, Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 2004; 29: 252–265
   PubMed Web of Science ®Google Scholar
• Clerc G. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine. Int Clin Psychopharmacol 2001; 16: 145–151
   PubMed Web of Science ®Google Scholar
• Costa D, Mogos I, Toma T. Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatr Scand Suppl 1985; 320: 85–92
   PubMedGoogle Scholar
• Dalton EJ, Rotondi D, Levitan RD, Kennedy SH, Brown GM. Use of slow-release melatonin in treatment-resistant depression. J Psychiatry Neurosci 2000; 25: 48–52
   PubMed Web of Science ®Google Scholar
• de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996; 57(Suppl 4)19–25
   PubMed Web of Science ®Google Scholar
• DeMartinis NA, Winokur A. Effects of psychiatric medications on sleep and sleep disorders. CNS Neurol Disord Drug Targets 2007; 6: 17–29
   PubMedGoogle Scholar
• den Boer JA, Bosker FJ, Meesters Y. Clinical efficacy of agomelatine in depression: the evidence. Int Clin Psychopharmacol 2006; 21(Suppl 1)S21–24
   PubMed Web of Science ®Google Scholar
• Dolberg OT, Hirschmann S, Grunhaus L. Melatonin for the treatment of sleep disturbances in major depressive disorder. Am J Psychiatry 1998; 155: 1119–1121
   PubMed Web of Science ®Google Scholar
• Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med 2006; 7: 17–24
   PubMed Web of Science ®Google Scholar
• Fainstein I, Bonetto A, Brusco LI, Cardinali DP. Effects of melatonin in elderly patients with sleep disturbance. A pilot study. Curr Ther Res 1997; 58: 990–1000
   Web of Science ®Google Scholar
• Fava M, Kendler KS. Major depressive disorder. Neuron 2000; 28: 335–341
   PubMed Web of Science ®Google Scholar
• Fuchs E, Simon M, Schmelting B. Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system. Int Clin Psychopharmacol 2006; 21(Suppl 1)S17–20
   Google Scholar
• Golden RN, Markey SP, Risby ED, Rudorfer MV, Cowdry RW, Potter WZ. Antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output. Arch Gen Psychiatry 1988; 45: 150–154
   PubMed Web of Science ®Google Scholar
• Guelfi JD, Ansseau M, Timmerman L, Korsgaard S. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 2001; 21: 425–431
   PubMed Web of Science ®Google Scholar
• Guilleminault C. Efficacy of agomelatine versus venlafaxine on subjective sleep of patients with major depressive disorder. Eur Neuropsychopharmacol 2005; 15(Suppl 3)S419
   Google Scholar
• Haddjeri N, Blier P, de Montigny C. Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine. Int Clin Psychopharmacol 1995; 10(Suppl 4)11–17
   PubMed Web of Science ®Google Scholar
• Hamon M, Bourgoin S. Pharmacological profile of antidepressants: a likely basis for their efficacy and side effects?. Eur Neuropsychopharmacol 16 Suppl 2006; 5: S625–S632
   Google Scholar
• Hirsch-Rodriguez E, Imbesi M, Manev R, Uz T, Manev H. The pattern of melatonin receptor expression in the brain may influence antidepressant treatment. Med Hypotheses. 2006; 69(1)120–4
   Web of Science ®Google Scholar
• Jindal RD, Thase ME. Treatment of insomnia associated with clinical depression. Sleep Med Rev 2004; 8: 19–30
   PubMed Web of Science ®Google Scholar
• Kayumov L, Brown G, Jindal R, Buttoo K, Shapiro CM. A randomized, double-blind, placebo-controlled crossover study of the effect of exogenous melatonin on delayed sleep phase syndrome. Psychosom Med 2001; 63: 40–48
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006; 16: 93–100
   PubMed Web of Science ®Google Scholar
• Kupfer DJ. Tricyclic antidepressants and EEG sleep in depressed patients. Typical and atypical antidepressants in clinical practice, E Costa, G Racagni. Raven Press, New York 1982; 269–279
   Google Scholar
• Kupfer DJ. Depression and associated sleep disturbances: patient benefits with agomelatine. Eur Neuropsychopharmacol 2006; 16(Suppl 5)S639–643
   Web of Science ®Google Scholar
• Kupfer DJ, Bowers MB, Jr. REM sleep and central monoamine oxidase inhibition. Psychopharmacologia 1972; 27: 183–190
   PubMed Web of Science ®Google Scholar
• Kupfer DJ, Spiker DG, Coble PA, Neil JF, Ulrich R, Shaw DH. Sleep and treatment prediction in endogenous depression. Am J Psychiatry 1981; 138: 429–434
   PubMed Web of Science ®Google Scholar
• Lam RW. Sleep disturbances and depression: a challenge for antidepressants. Int Clin Psychopharmacol 2006; 21(Suppl 1)S25–29
   PubMed Web of Science ®Google Scholar
• Larson J, Jessen RE, Uz T, et al. Impaired hippocampal long-term potentiation in melatonin MT2 receptor-deficient mice. Neurosci Lett 2006; 393: 23–26
   PubMed Web of Science ®Google Scholar
• Leproult R, Van Onderbergen A, L'hermite-Baleriaux M, Van Cauter E, Copinschi G. Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol (Oxford) 2005; 63: 298–304
   PubMed Web of Science ®Google Scholar
• Loo H, Hale A, D'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002; 17: 239–247
   PubMed Web of Science ®Google Scholar
• Lopes MC, Quera-Salva MA, Guilleminault C. Cycling alternating pattern in the NREM sleep of patients within major depressive disorder: baseline results and change overtime with a new antidepressant. Sleep Med 2005; 6(suppl. 2)87–88
   PubMedGoogle Scholar
• Lustberg L, Reynolds CF. Depression and insomnia: questions of cause and effect. Sleep Med Rev 2000; 4: 253–262
   PubMed Web of Science ®Google Scholar
• Luthringer R, Toussaint M, Schaltenbrand N, et al. A double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression. Psychopharmacol Bull 1996; 32: 637–646
   PubMed Web of Science ®Google Scholar
• Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol 2005; 20: 533–559
   PubMed Web of Science ®Google Scholar
• McClung CA. Circadian genes, rhythms and the biology of mood disorders. Pharmacol Ther 2007; 114: 222–232
   PubMed Web of Science ®Google Scholar
• Millan MJ. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006; 110: 135–370
   PubMed Web of Science ®Google Scholar
• Millan MJ, Brocco M, Gobert A, Dekeyne A. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berlin) 2005; 177: 448–458
   PubMed Web of Science ®Google Scholar
• Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098. is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306: 954–964
   PubMed Web of Science ®Google Scholar
• Moltzen EK, Bang-Andersen B. Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century – A medicinal chemistry survey. Curr Top Med Chem 2006; 6: 1801–1823
   PubMed Web of Science ®Google Scholar
• Montgomery SA. Major depressive disorders: clinical efficacy and tolerability of agomelatine, a new melatonergic agonist. Eur Neuropsychopharmacol 2006; 16(Suppl 5)S633–638
   Google Scholar
• Monti, JM. 1989. Effect of a reversible monoamine oxidase-A inhibitor (moclobemide) on sleep of depressed patients. Br J Psychiatry. Suppl: 61–65.
   Google Scholar
• Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997; 349: 1498–1504
   PubMed Web of Science ®Google Scholar
• Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 2002; 34: 13–25
   PubMed Web of Science ®Google Scholar
• Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999; 60: 256–259
   PubMed Web of Science ®Google Scholar
• Pandi-Perumal SR, Srinivasan V, Cardinali DP, Monti JM. Could agomelatine be the ideal antidepressant?. Expert Review Neurotherapeutics 2006; 6(11)1595–1608
   PubMedGoogle Scholar
• Pandi-Perumal SR, Srinivasan V, Poeggeler B, Hardeland R, Cardinali DP. Drug Insight: The use of melatonergic agonists for the treatment of insomnia – Focus on ramelteon. Nat Clin Pract Neurol 2007; 3(4)221–228
   PubMedGoogle Scholar
• Papakostas GI, Thase ME, Fava M, Craig Nelson J, Shelton RC. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer ggents. Biol Psychiatry. 2007; 62(11)1217–1227
   PubMed Web of Science ®Google Scholar
• Pjrek E, Winkler D, Konstantinidis A, Willeit M, Praschak-Rieder N, Kasper S. Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology (Berlin) 2007; 190: 575–579
   PubMed Web of Science ®Google Scholar
• Quera-Salva MA, Vanier B, Chapotot F. Effect of agomelatine on the sleep EEG in patients with major depressive disorders (MDD). Eur Neuropsychopharmacol 2005; 15(Suppl 3)S435
   PubMed Web of Science ®Google Scholar
• Quera-Salva MA, Vanier B, Laredo J, et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol 2007; 10(5)691–696
   PubMed Web of Science ®Google Scholar
• Redman JR, Francis AJ. Entrainment of rat circadian rhythms by the melatonin agonist S-20098 requires intact suprachiasmatic nuclei but not the pineal. J Biol Rhythms 1998; 13: 39–51
   PubMed Web of Science ®Google Scholar
• Ridout F, Shamsi Z, Meadows R, Johnson S, Hindmarch I. A single-center, randomized, double-blind, placebo-controlled, crossover investigation of the effects of fexofenadine hydrochloride 180 mg alone and with alcohol, with hydroxyzine hydrochloride 50 mg as a positive internal control, on aspects of cognitive and psychomotor function related to driving a car. Clin Ther 2003; 25: 1518–1538
   PubMed Web of Science ®Google Scholar
• Rosenzweig-Lipson S, Beyer CE, Hughes ZA, et al. Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther 2007; 113: 134–153
   PubMed Web of Science ®Google Scholar
• Roth T, Stubbs C, Walsh JK. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 2005; 28: 303–307
   PubMed Web of Science ®Google Scholar
• Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 2006; 7: 312–318
   PubMed Web of Science ®Google Scholar
• Rouillon F. Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Int Clin Psychopharmacol 2006; 21(Suppl 1)S31–35
   PubMedGoogle Scholar
• Ruigt GS, Kemp B, Groenhout CM, Kamphuisen HA. Effect of the antidepressant Org 3770 on human sleep. Eur J Clin Pharmacol 1990; 38: 551–554
   PubMed Web of Science ®Google Scholar
• Rush AJ, Armitage R, Gillin JC, et al. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biol Psychiatry 1998; 44: 3–14
   PubMed Web of Science ®Google Scholar
• Sack RL, Lewy AJ. Desmethylimipramine treatment increases melatonin production in humans. Biol Psychiatry 1986; 21: 406–410
   PubMed Web of Science ®Google Scholar
• Salin-Pascual RJ, Galicia-Polo L, Drucker-Colin R. Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers. J Clin Psychiatry 1997; 58: 348–350
   PubMed Web of Science ®Google Scholar
• Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 2005; 437: 1257–1263
   PubMed Web of Science ®Google Scholar
• Scharf MB, Sachais BA. Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients. J Clin Psychiatry 1990; 51(Suppl)13–17
   PubMedGoogle Scholar
• Schatzberg AF, Kremer C, Rodrigues HE, Murphy GM, Jr. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 2002; 10: 541–550
   PubMed Web of Science ®Google Scholar
• Schulz H, Lund R, Cording C, Dirlich G. Bimodal distribution of REM sleep latencies in depression. Biol Psychiatry 1979; 14(4)595–600
   PubMed Web of Science ®Google Scholar
• Sharpley AL, Cowen PJ. Effect of pharmacologic treatments on the sleep of depressed patients. Biol Psychiatry 1995; 37: 85–98
   PubMed Web of Science ®Google Scholar
• Sharpley AL, Williamson DJ, Attenburrow ME, Pearson G, Sargent P, Cowen PJ. The effects of paroxetine and nefazodone on sleep: a placebo controlled trial. Psychopharmacology (Berlin) 1996; 126: 50–54
   PubMed Web of Science ®Google Scholar
• Shen J, Chung SA, Kayumov L, et al. Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine. Can J Psychiatry 2006; 51: 27–34
   PubMed Web of Science ®Google Scholar
• Shorter, E. 2007. The doctrine of the two depressions in historical perspective. Acta Psychiatr Scand. Suppl: 5–13.
   Google Scholar
• Smith WT, Londborg PD, Glaudin V, Painter JR. Is extended clonazepam cotherapy of fluoxetine effective for outpatients with major depression?. J Affect Disord 2002; 70: 251–259
   PubMed Web of Science ®Google Scholar
• Srinivasan V. Psychoactive drugs, pineal gland and affective disorders. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13: 653–664
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Smits M, Spence W, et al. Melatonin in mood disorders. World J Biol Psychiatry 2006; 7: 138–151
   PubMed Web of Science ®Google Scholar
• Stahl, S. Essential psychopharmacology. Cambridge, MA: Cambridge University Press.
   Google Scholar
• Stahl SM, Zhang L, Damatarca C, Grady M. Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. J Clin Psychiatry 2003; 64(Suppl 14)6–17
   Google Scholar
• Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005; 10: 732–747
   PubMed Web of Science ®Google Scholar
• Staner L, Kerkhofs M, Detroux D, Leyman S, Linkowski P, Mendlewicz J. Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression. Sleep 1995; 18: 470–477
   PubMed Web of Science ®Google Scholar
• Szymanska A, Rabe-Jablonska J, Karasek M. Diurnal profile of melatonin concentrations in patients with major depression: relationship to the clinical manifestation and antidepressant treatment. Neuro Endocrinol Lett 2001; 22: 192–198
   PubMed Web of Science ®Google Scholar
• Thase ME. Pharmacotherapy of bipolar depression: an update. Curr Psychiatry Rep 2006; 8: 478–488
   PubMedGoogle Scholar
• Thompson C, Mezey G, Corn T, et al. The effect of desipramine upon melatonin and cortisol secretion in depressed and normal subjects. Br J Psychiatry 1985; 147: 389–393
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Armitage R, et al. Effects of fluoxetine on the polysomnogram in outpatients with major depression. Neuropsychopharmacology 1999; 20: 447–459
   PubMed Web of Science ®Google Scholar
• Tsuno N, Besset A, Ritchie K. Sleep and depression. J Clin Psychiatry 2005; 66: 1254–1269
   PubMed Web of Science ®Google Scholar
• Tuma J, Strubbe JH, Mocaer E, Koolhaas JM. S20098 affects the free-running rhythms of body temperature and activity and decreases light-induced phase delays of circadian rhythms of the rat. Chronobiol Int 2001; 18: 781–799
   PubMed Web of Science ®Google Scholar
• Tuunainen A, Kripke DF, Elliott JA, et al. Depression and endogenous melatonin in postmenopausal women. J Affect Disord 2002; 69: 149–158
   PubMed Web of Science ®Google Scholar
• Van Reeth O, Weibel L, Olivares E, Maccari S, Mocaer E, Turek FW. Melatonin or a melatonin agonist corrects age-related changes in circadian response to environmental stimulus. Am J Physiol Regul Integr Comp Physiol 2001; 280: R1582–1591
   Web of Science ®Google Scholar
• Venkoba rao A, Parvathi Devi S, Srinivasan V. Urinary melatonin in depression. Indian J Psychiatry 1983; 25: 167–172
   PubMedGoogle Scholar
• Vogel GW, Buffenstein A, Minter K, Hennessey A. Drug effects on REM sleep and on endogenous depression. Neurosci Biobehav Rev 1990; 14: 49–63
   PubMed Web of Science ®Google Scholar
• Ware JC, Brown FW, Moorad PJ, Jr, Pittard JT, Cobert B. Effects on sleep: a double-blind study comparing trimipramine to imipramine in depressed insomniac patients. Sleep 1989; 12: 537–549
   PubMed Web of Science ®Google Scholar
• Wehr TA, Wirz-Justice A, Goodwin FK, Duncan W, Gillin JC. Phase advance of the circadian sleep-wake cycle as an antidepressant. Science. 1979; 206(4419)710–3
   PubMed Web of Science ®Google Scholar
• Weibel L, Turek FW, Mocaer E, Van Reeth O. A melatonin agonist facilitates circadian resynchronization in old hamsters after abrupt shifts in the light-dark cycle. Brain Res 2000; 880: 207–211
   PubMed Web of Science ®Google Scholar
• Wichniak A, Riemann D, Kiemen A, Voderholzer U, Jernajczyk W. Comparison between eye movement latency and REM sleep parameters in major depression. Eur Arch Psychiatry Clin Neurosci 2000; 250: 48–52
   PubMed Web of Science ®Google Scholar
• Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs 2005; 65: 927–947
   PubMed Web of Science ®Google Scholar
• Winokur A, Sateia MJ, Hayes JB, Bayles-Dazet W, MacDonald MM, Gary KA. Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study. Biol Psychiatry 2000; 48: 75–78
   PubMed Web of Science ®Google Scholar
• Winokur A, Gary KA, Rodner S, Rae-Red C, Fernando AT, Szuba MP. Depression, sleep physiology, and antidepressant drugs. Depress Anxiety 2001; 14: 19–28
   PubMed Web of Science ®Google Scholar
• Winokur A, DeMartinis NA III, McNally DP, Gary EM, Cormier JL, Gary KA. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry 2003; 64: 1224–1229
   PubMed Web of Science ®Google Scholar
• Wirz-Justice A. Biological rhythm disturbances in mood disorders. Int Clin Psychopharmacol 2006; 21(Suppl 1)S11–15
   PubMed Web of Science ®Google Scholar
• Yang C, White DP, Winkelman JW. Antidepressants and periodic leg movements of sleep. Biol Psychiatry 2005; 58: 510–514
   PubMed Web of Science ®Google Scholar
• Zupancic M, Guilleminault C. Agomelatine: a preliminary review of a new antidepressant. CNS Drugs 2006; 20: 981–992
   PubMed Web of Science ®Google Scholar